Recent advancements in diabetic retinopathy treatment from the diabetic retinopathy clinical research network

Current Opinion in Ophthalmology

Volumn 27, Issue 3, 2016, Pages 210-216

  Baker, Carl W ^a   Jiang, Yi ^b   Stone, Thomas ^b  

^a Paducah Retinal Center   (United States)

^b Retina Assoc of Kentucky   (United States)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Intravitreal injection

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; LASER COAGULATION; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; REPRODUCIBILITY; REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; COMPLICATION; HEMORRHAGE; HUMAN; PATHOPHYSIOLOGY; VISION DISORDERS;

DIABETIC RETINOPATHY; HEMORRHAGE; HUMANS; LASER COAGULATION; VISION DISORDERS; VISUAL ACUITY;

EID: 84959110147     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000262     Document Type: Review

References (23)

1. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125:469-480.
2. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447-1449.
3. Diabetic Retinopathy Clinical Research Network. A Phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
4. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2008; 117:1064-1077.
5. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
6. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt vs deferred laser treatment: 3-year randomized trial results. Ophthalmology 2012; 119:2312-2318.
7. Elman M, Ayala A, Bressler N, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment-5-year randomized trial results. Ophthalmology 2015; 122:375-381.
8. Aiello L, Ayala A, Antoszyk A, et al. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control a randomized clinical trial. JAMA Ophthalmol 2015; 133:888-896.
9. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013; 131:283-293.
10. Bhavsar A, Torres K, Glassman A, et al. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol 2014; 132:889-890.
11. Bressler S, Edwards A, Chalam K, et al. Reproducibility of spectral domain optical coherence tomography retinal thickness measurements and conversion to equivalent time domain metrics in diabetic macular edema. JAMA Ophthalmol 2014; 132:1113-1122.
12. Bressler SB, Edwards AR, Andreoli CM, et al. Reproducibility of optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss stratus metrics in diabetic macular edema. Transl Vis Sci Technol 2015; 4:5.
13. Friedman S, Almukhtar T, Baker C, et al. Topical nepafenac in eyes with noncentral diabetic macular edema. Retina 2015; 35:944-956.
14. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015; 314:2137-2146.
15. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372:1193-1203.
16. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114:525-536.
17. Browning DJ, Apte RS, Bressler SB, et al. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina 2009; 29:300-305.
18. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103:1796-1806.
19. Bressler NM for the DRCR Network. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema.a Presented at the AAO Sub-Specialty Day Meeting November 2015, Las Vegas, NV, USA.
20. The Diabetic Retinopathy Study research group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976; 81:383-396.
21. Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131:1033-1040.
22. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012; 130:1145-1152.
23. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015; 122:2044-2052.